Review
Endocrinology & Metabolism
Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Miao Yu
Summary: This meta-analysis suggests that dipeptidyl peptidase-4 (DPP4) inhibitors are more effective than other oral antidiabetic drugs in reducing glycemic variability, as measured by mean amplitude of glycemic excursions (MAGE), in type 2 diabetes mellitus patients without concurrent insulin treatments.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Multidisciplinary Sciences
Tomoya Mita, Naoto Katakami, Hidenori Yoshii, Tomio Onuma, Hideaki Kaneto, Takeshi Osonoi, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yutaka Umayahara, Tsunehiko Yamamoto, Hiroki Yokoyama, Nobuichi Kuribayashi, Hideaki Jinnouchi, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada
Summary: This study investigated whether early initiation of alogliptin improved long-term cardiovascular outcomes. The results showed that early use of alogliptin was not associated with a reduced risk of composite cardiovascular disease, which could be attributed to fewer events and/or the addition of DPP-4 inhibitors during the follow-up period.
SCIENTIFIC REPORTS
(2023)
Article
Medicine, General & Internal
Mingtong Xu, Kan Sun, Wenjie Xu, Chuan Wang, Dewen Yan, Shu Li, Li Cong, Yinzhen Pi, Weihong Song, Qingyuan Sun, Rijun Xiao, Weixia Peng, Jianping Wang, Hui Peng, Yawei Zhang, Peng Duan, Meiying Zhang, Jianying Liu, Qingmei Huang, Xuefeng Li, Yan Bao, Tianshu Zeng, Kun Wang, Li Qin, Chaoming Wu, Chunying Deng, Chenghu Huang, Shuang Yan, Wei Zhang, Meizi Li, Li Sun, Yanjun Wang, Hongmei Li, Guang Wang, Shuguang Pang, Xianling Zheng, Haifang Wang, Fujun Wang, Xiuhai Su, Yujin Ma, Wei Zhang, Ziling Li, Zuoling Xie, Ning Xu, Lin Ni, Li Zhang, Xiangqun Deng, Tianrong Pan, Qijuan Dong, Xiaohong Wu, Xingping Shen, Xin Zhang, Qijing Zou, Chengxia Jiang, Jue Xi, Jianhua Ma, Jingchao Sun, Li Yan
Summary: The study aimed to evaluate the efficacy and safety of a novel DPP-4 inhibitor, fotagliptin, in treatment-naive patients with T2DM. The results demonstrated that fotagliptin was non-inferior to alogliptin in improving glycemic control, with significantly more patients in the fotagliptin and alogliptin groups achieving HbA1c < 7.0% after 24 weeks of treatment.
Article
Endocrinology & Metabolism
Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Linong Ji
Summary: This meta-analysis summarizes the effects of DPP4 inhibitors on glucagon levels in patients with type 2 diabetes mellitus (T2DM). The results show that DPP4 inhibitors can significantly reduce postprandial glucagon levels in T2DM patients.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Xi Chen, Bin Xue, Shadma Wahab, Armiya Sultan, Mohammad Khalid, Song Yang
Summary: In this study, a potential DPP4 inhibitor, SRT2183, was identified using computational methods and validated through molecular docking and molecular dynamics simulations.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Endocrinology & Metabolism
Kohjiro Ueki, Yukio Tanizawa, Jiro Nakamura, Yuichiro Yamada, Nobuya Inagaki, Hirotaka Watada, Iichiro Shimomura, Rimei Nishimura, Hideaki Miyoshi, Atsuko Abiko, Hideki Katagiri, Michio Hayashi, Akira Shimada, Keiko Naruse, Shimpei Fujimoto, Masazumi Fujiwara, Kenichi Shikata, Yosuke Okada, Eiichi Araki, Tsutomu Yamazaki, Takashi Kadowaki
Summary: This study aimed to investigate the long-term safety and efficacy of alogliptin in treating patients with type 2 diabetes in the real-world setting. The results showed that alogliptin was safe and effective when used alone or with other oral hypoglycemic agents.
BMJ OPEN DIABETES RESEARCH & CARE
(2021)
Article
Physiology
Takeshi Hasegawa, Junhui Zhao, Brian Bieber, Jarcy Zee, Ronald L. Pisoni, Bruce M. Robinson, Norio Hanafusa, Masaomi Nangaku
Summary: The study observed a gradual increase in DPP-4 inhibitor prescriptions among Japanese hemodialysis patients with diabetes mellitus over the study years, while also finding that DPP-4 inhibitors could improve ESA resistance in HD patients without iron deficiency.
KIDNEY & BLOOD PRESSURE RESEARCH
(2021)
Review
Endocrinology & Metabolism
Qizhi Tang, Weiyu Pan, Liangyue Peng
Summary: The study provides preliminary evidence regarding the similarity in the efficacy of evogliptin compared to other DPP-4i drugs, including sitagliptin and linagliptin, for managing HbA1c levels and adverse events.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Shangyu Chai, Ruya Zhang, Richard David Carr, Carolyn F. Deacon, Yiman Zheng, Swapnil Rajpathak, Jingya Chen, Miao Yu
Summary: This meta-analysis showed that DPP4 inhibitors effectively increase both fasting and postprandial GIP concentrations in T2DM patients, with consistent results in sensitivity analyses. Subgroup analyses indicated that study characteristics did not significantly impact the influence of DPP4 inhibitors on GIP levels in T2DM patients.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Chen-Yi Wu, Chun-Ying Wu, Chung-Pin Li, Yiing-Jenq Chou, Yi-Hsian Lin, Yun-Ting Chang
Summary: This study found that diabetic patients treated with DPP4 inhibitors had a significantly increased risk of bullous pemphigoid, especially when used concurrently with insulin.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2021)
Article
Immunology
Yuichiro Iwamoto, Takatoshi Anno, Katsumasa Koyama, Fumiko Kawasaki, Kohei Kaku, Koichi Tomoda, Seiko Sugiyama, Yumi Aoyama, Hideaki Kaneto
Summary: DPP-4 inhibitors are closely associated with bullous pemphigoid (BP) and may lead to disruption of immune tolerance. Checking autoimmune antibodies may be important in DPP-4i-related BP, even when symptoms improve.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Endocrinology & Metabolism
Tsuyoshi Okura, Yohei Fujioka, Risa Nakamura, Yuichi Ito, Sonoko Kitao, Mari Anno, Kazuhisa Matsumoto, Kyoko Shoji, Hiroko Okura, Kazuhiko Matsuzawa, Shoichiro Izawa, Etsuko Ueta, Masahiko Kato, Takeshi Imamura, Shin-ichi Taniguchi, Kazuhiro Yamamoto
Summary: The study suggests that treatment with DPP4i may improve insulin resistance without changing insulin secretion.
DIABETOLOGY & METABOLIC SYNDROME
(2022)
Article
Cardiac & Cardiovascular Systems
Qu Chen, Dandan Jiang, Zhonggui Shan
Summary: This study investigated the effects of dipeptidyl peptidase-4 inhibitors (DPP4i) on the progression of type B intramural hematoma (IMHB) in patients with diabetes mellitus (DM). The study found that DM patients with IMHB who received DPP4i treatment had lower aorta-related mortality and a more benign progression compared to those who did not receive DPP4i or those without DM. Furthermore, a higher eosinophil count and a lower neutrophil to lymphocyte ratio (NLR) were identified as potential protective factors that may explain the therapeutic benefits of DPP4i.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Endocrinology & Metabolism
So-Hee Park, Han Eol Jeong, In-Sun Oh, Sang-Mo Hong, Sung Hoon Yu, Chang Beom Lee, Ju-Young Shin
Summary: This population-based cohort study found that compared with glimepiride, the use of evogliptin did not increase the risk of cardiovascular events, including cerebrovascular events, myocardial infarction, heart failure, transient ischaemic attack, and angina pectoris.
DIABETES OBESITY & METABOLISM
(2021)
Review
Medicine, General & Internal
Carlos Campos, Jeff Unger
Summary: GLP-1RAs and DPP4is are two common classes of medications for the treatment of type 2 diabetes, acting through increasing glucose-dependent insulin secretion and inhibiting peptidase activity, respectively. GLP-1RAs have high glycemic efficacy and weight loss effects, with predominantly transient gastrointestinal adverse events; while DPP4is provide moderate glycemic control but do not offer cardiovascular benefits, with good tolerability.
POSTGRADUATE MEDICINE
(2021)